Alteogen

Alteogen Financial Leverage

The Financial Leverage (Equity Multiplier) of Alteogen (196170.KQ) as of Nov 13, 2026 is 1.57. In the previous year, Financial Leverage (Equity Multiplier) was 1.49 — a change of 4.99% (higher).

Financial Leverage

1.57

YoY

4.99%

Last updated:

Financial Leverage (Equity Multiplier) of Alteogen is 2025 1.57 . Financial Leverage (Equity Multiplier) of Alteogen was 2024 1.49 . It decreases by 4.99% higher compared to the previous year.

The Alteogen Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.07 KRW
Jan 1, 2019
1.23 KRW
Jan 1, 2020
1.21 KRW
Jan 1, 2021
1.90 KRW
Jan 1, 2022
1.65 KRW
Jan 1, 2023
1.73 KRW
Jan 1, 2024
1.49 KRW
Jan 1, 2025
1.57 KRW
The Alteogen Financial Leverage history
YEARFinancial LeverageYoY
1.57+4.99%
1.49-13.54%
1.73+4.78%
1.65-13.33%
1.90+56.86%
1.21-1.20%
1.23+14.67%
1.07-0.75%
1.08+1.83%
1.06+3.77%
1.02-3.58%
1.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alteogen Stock analysis

What does Alteogen do? Alteogen, Inc. generates revenue through its biobetter business segment, developing protein pharmaceuticals and cancer therapies, and its bio similar business segment, focusing on bio similar and animal medicines. The company sells growth hormone, herceptin, humira, antibodies, and other products primarily to healthcare providers and pharmaceutical distributors. Its biobetter segment targets oncology and protein-based treatments, while the bio similar segment serves both human and animal health markets with cost-effective alternatives to branded drugs. The firm's product portfolio includes growth hormone, herceptin, and humira, which are key revenue drivers in the biopharmaceutical sector. Herceptin and humira are well-established anticancer drugs, while growth hormone addresses endocrine disorders. The company's bio similar segment offers affordable versions of these therapies, appealing to budget-conscious healthcare systems and veterinary markets. Sales are concentrated in the human and animal medicine sectors, leveraging its dual focus on biobetter and bio similar products. Alteogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alteogen stock

Financial Leverage (Equity Multiplier) of Alteogen is 1.57 in 2025.

Financial Leverage (Equity Multiplier) of Alteogen changed from 1.49 to 1.57, representing a 4.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Alteogen since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Alteogen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Alteogen

All Key Metrics — Alteogen